Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Caredx Inc (NQ: CDNA )

23.65 -0.23 (-0.96%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Caredx Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
CareDx Reports Third Quarter 2024 Results and Raises Revenue Guidance
From CareDx, Inc.
Via Business Wire
CareDx and Dovetail Genomics Announce Strategic Partnership to Drive Next Wave of Innovation in Transplant Matching with Cutting-Edge Hi-C Technology
From CareDx, Inc.
Via Business Wire
CareDx Showcases Latest Advancements Across its HLA Typing Solutions at Annual American Society for Histocompatibility and Immunogenetics Meeting
From CareDx, Inc.
Via Business Wire
CareDx Reports Preliminary Financial Results for Third Quarter 2024
From CareDx, Inc.
Via Business Wire
CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From CareDx, Inc.
Via Business Wire
CareDx Appoints Jing Huang Chief Data and AI Officer
From CareDx, Inc.
Via Business Wire
CareDx to Host Investor Day on October 15, 2024
From CareDx, Inc.
Via Business Wire
CareDx Announces Closure of DOJ Investigation with No Finding of Wrongdoing
From CareDx, Inc.
Via Business Wire
CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From CareDx, Inc.
Via Business Wire
CareDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From CareDx, Inc.
Via Business Wire
CareDx Appoints Keith Kennedy Chief Operating Officer and Jessica Meng Chief Commercial Officer
From CareDx, Inc.
Via Business Wire
CareDx Announces Transplant Community Secures Win Reaffirming Longstanding Medicare Coverage for AlloSure and AlloMap Testing
From CareDx, Inc.
Via Business Wire
CareDx Reports Second Quarter 2024 Results and Increases Revenue Guidance
From CareDx, Inc.
Via Business Wire
CareDx to Report Second Quarter 2024 Financial Results
From CareDx, Inc.
Via Business Wire
Landmark Independent Publication in Nature Medicine Validates CareDx AlloView AI-Enabled Risk Prediction Model and Demonstrates AlloSure Kidney Detects Subclinical Rejection in Stable Patients
From CareDx, Inc.
Via Business Wire
AI Integration and Real-World Utility of CareDx Portfolio Highlighted in New Data at the 2024 American Transplant Congress
From CareDx, Inc.
Via Business Wire
CareDx Reiterates Position that it Does Not Infringe the ‘544 Patent, Injunction Motion is Irrelevant
From CareDx, Inc.
Via Business Wire
CareDx to Participate in Upcoming Investor Conferences
From CareDx, Inc.
Via Business Wire
Landmark Study Shows CareDx’s HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer Biopsies
From CareDx, Inc.
Via Business Wire
CareDx Reports First Quarter 2024 Results
From CareDx, Inc.
Via Business Wire
CareDx Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From CareDx, Inc.
Via Business Wire
CareDx to Report First Quarter 2024 Financial Results
From CareDx, Inc.
Via Business Wire
CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From CareDx, Inc.
Via Business Wire
CareDx Appoints John W. Hanna as its New President and Chief Executive Officer
From CareDx, Inc.
Via Business Wire
CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting
From CareDx, Inc.
Via Business Wire
CareDx Appoints Bryan Riggsbee to Its Board of Directors
From CareDx, Inc.
Via Business Wire
CareDx Announces Fourth Quarter and Full Year 2023 Financial Results
From CareDx, Inc.
Via Business Wire
CareDx to Participate in the Raymond James & Associates’ 45th Annual Institutional Investors Conference
From CareDx, Inc.
Via Business Wire
CareDx to Report Fourth Quarter and Full Year 2023 Financial Results
From CareDx, Inc.
Via Business Wire
CareDx Showcases Digital Solutions and Pipeline in Cellular Transplant and Therapy Monitoring at the 2024 Tandem Meetings
From CareDx, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.